JP2024508762A5 - - Google Patents
Info
- Publication number
- JP2024508762A5 JP2024508762A5 JP2023549819A JP2023549819A JP2024508762A5 JP 2024508762 A5 JP2024508762 A5 JP 2024508762A5 JP 2023549819 A JP2023549819 A JP 2023549819A JP 2023549819 A JP2023549819 A JP 2023549819A JP 2024508762 A5 JP2024508762 A5 JP 2024508762A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- pharmaceutical composition
- amino acid
- acid sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163150832P | 2021-02-18 | 2021-02-18 | |
| US63/150,832 | 2021-02-18 | ||
| US202163180896P | 2021-04-28 | 2021-04-28 | |
| US63/180,896 | 2021-04-28 | ||
| US202163226041P | 2021-07-27 | 2021-07-27 | |
| US63/226,041 | 2021-07-27 | ||
| US202163285785P | 2021-12-03 | 2021-12-03 | |
| US63/285,785 | 2021-12-03 | ||
| PCT/US2022/016840 WO2022178158A1 (en) | 2021-02-18 | 2022-02-17 | Anti-tl1a antibody compositions and methods of treatment in the lung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024508762A JP2024508762A (ja) | 2024-02-28 |
| JP2024508762A5 true JP2024508762A5 (enExample) | 2025-02-26 |
Family
ID=82931034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023549819A Pending JP2024508762A (ja) | 2021-02-18 | 2022-02-17 | 抗ｔｌ１ａ抗体組成物及び肺における治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240336691A1 (enExample) |
| EP (1) | EP4294443A4 (enExample) |
| JP (1) | JP2024508762A (enExample) |
| KR (1) | KR20230158494A (enExample) |
| AU (1) | AU2022221712A1 (enExample) |
| BR (1) | BR112023016574A2 (enExample) |
| CA (1) | CA3207818A1 (enExample) |
| MX (1) | MX2023009681A (enExample) |
| TW (1) | TW202302640A (enExample) |
| WO (1) | WO2022178158A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| AU2020275413A1 (en) | 2019-05-14 | 2021-12-23 | Cedars-Sinai Medical Center | TL1A patient selection methods, systems, and devices |
| NZ787680A (en) | 2019-10-24 | 2026-02-27 | Cedars Sinai Medical Center | Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof |
| CN120917045A (zh) * | 2023-02-17 | 2025-11-07 | 普罗米修斯生物科学公司 | 治疗皮肤的抗tl1a抗体组合物和方法 |
| WO2024173865A2 (en) * | 2023-02-17 | 2024-08-22 | Prometheus Biosciences, Inc. | Anti-tl1a antibody compositions and methods of treatment in the kidney |
| WO2024173877A1 (en) * | 2023-02-17 | 2024-08-22 | Prometheus Biosciences, Inc. | Anti-tl1a antibody compositions and methods of treatment in the liver |
| EP4676971A2 (en) * | 2023-03-09 | 2026-01-14 | Prometheus Biosciences, Inc. | Anti-tl1a antibody compositions and methods of treatment for sarcoidosis |
| CN121843714A (zh) | 2023-08-11 | 2026-04-10 | 派拉冈医疗公司 | Tl1a结合抗体及使用方法 |
| US20250109209A1 (en) | 2023-10-03 | 2025-04-03 | Absci Corporation | Tl1a associated antibody compositions and methods of use |
| JP2025115976A (ja) | 2024-01-26 | 2025-08-07 | フューチャージェン・バイオファーマシューティカル（ベイジン）カンパニー・リミテッド | Ｔｌ１ａに特異的に結合できる抗体及びその使用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005018571A2 (en) * | 2003-08-20 | 2005-03-03 | University Of Miami | Compositions and methods for treating inflammatory lung disease |
| WO2009114110A1 (en) * | 2008-03-08 | 2009-09-17 | Immungene, Inc. | Engineered fusion molecules immunotherapy in cancer and inflammatory diseases |
| JO3375B1 (ar) * | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
| WO2014106602A1 (en) * | 2013-01-02 | 2014-07-10 | Glenmark Pharmaceuticals S.A. | Antibodies that bind to tl1a and their uses |
| US9683998B2 (en) * | 2013-11-13 | 2017-06-20 | Pfizer Inc. | Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof |
| TWI703158B (zh) * | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| KR20190082815A (ko) * | 2016-10-26 | 2019-07-10 | 세다르스-신나이 메디칼 센터 | 중화 항-tl1a 단일 클론 항체 |
| WO2018195328A1 (en) * | 2017-04-20 | 2018-10-25 | Cedars-Sinai Medical Center | Methods of predicting non-response to anti-tnf treatment in subjects with inflammatory bowel disease |
| CN112585165B8 (zh) * | 2018-04-25 | 2025-02-14 | 普罗米修斯生物科学公司 | 优化的抗tl1a抗体 |
| AU2020275413A1 (en) * | 2019-05-14 | 2021-12-23 | Cedars-Sinai Medical Center | TL1A patient selection methods, systems, and devices |
| NZ787680A (en) * | 2019-10-24 | 2026-02-27 | Cedars Sinai Medical Center | Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof |
-
2022
- 2022-02-17 MX MX2023009681A patent/MX2023009681A/es unknown
- 2022-02-17 AU AU2022221712A patent/AU2022221712A1/en active Pending
- 2022-02-17 US US18/546,947 patent/US20240336691A1/en active Pending
- 2022-02-17 TW TW111105899A patent/TW202302640A/zh unknown
- 2022-02-17 JP JP2023549819A patent/JP2024508762A/ja active Pending
- 2022-02-17 WO PCT/US2022/016840 patent/WO2022178158A1/en not_active Ceased
- 2022-02-17 KR KR1020237031713A patent/KR20230158494A/ko active Pending
- 2022-02-17 BR BR112023016574A patent/BR112023016574A2/pt unknown
- 2022-02-17 EP EP22756948.0A patent/EP4294443A4/en active Pending
- 2022-02-17 CA CA3207818A patent/CA3207818A1/en active Pending